Vor Biopharma Inc. (VOR)Healthcare | Biotechnology | Boston, United States | NasdaqGS
18.03 USD
-1.11
(-5.799%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:03 a.m. EDT
The investment case for Vor Biopharma is currently defined by a stark divergence between a recovering price chart and deteriorating fundamentals. Over the last four years, the stock has lost 86% of its value, reflecting a brutal multi-year decline where the market punished the business repeatedly. However, the most recent annual data shows a massive 155% rebound, suggesting the worst of the structural decay may be behind the company or that a specific catalyst has temporarily restored confidence. This recovery is the only bright spot in an otherwise bleak picture characterized by negative earnings, negative free cash flow, and a negative book value. The balance sheet appears technically robust due to high cash reserves relative to debt, but the ongoing burn rate and lack of profitability indicate a high-risk speculative environment rather than a stable income generator. With no dividend to provide a floor, investors are entirely exposed to the volatility of clinical trials or regulatory approvals. The recent surge has lifted the price significantly above its moving averages, creating a crowded trade that leaves little room for error if the next quarterly results fail to sustain the momentum. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.092029 |
| MSTL | 0.096272 |
| AutoETS | 0.101283 |
| AutoARIMA | 0.101305 |
| MSTL_60 | 0.146219 |
| MSTL_126 | 0.197687 |
| MSTL_60_126 | 0.276182 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 21% |
| H-stat | 7.38 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 0.75 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 976,971,392 |
| Forward P/E | -4.82 |
| Beta | 1.70 |
| Website | https://www.vorbio.com |
As of July 11, 2026, 5:03 a.m. EDT: With no options data available in the input, there is no evidence of speculative positioning regarding implied volatility, open interest concentration, or unusual flow. The absence of data prevents inferring whether traders are hedging downside or betting on a specific catalyst.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5995816 |
| Address1 | 500 Boylston Street |
| Address2 | Suite 1350 |
| All Time High | 1,272.4 |
| All Time Low | 2.62 |
| Ask | 22.88 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 2,650,410 |
| Average Daily Volume3 Month | 1,214,273 |
| Average Volume | 1,214,273 |
| Average Volume10Days | 2,650,410 |
| Beta | 1.695 |
| Bid | 13.6 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | -2.776 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 18.03 |
| Current Ratio | 31.149 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 19.33 |
| Day Low | 17.82 |
| Display Name | Vor Biopharma |
| Earnings Timestamp | 1,778,675,400 |
| Earnings Timestamp End | 1,786,710,600 |
| Earnings Timestamp Start | 1,786,710,600 |
| Ebitda | -341,715,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.429 |
| Enterprise Value | 488,385,376 |
| Eps Current Year | -6.90122 |
| Eps Forward | -3.74217 |
| Eps Trailing Twelve Months | -70.4 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 15.5804 |
| Fifty Day Average Change | 2.4496002 |
| Fifty Day Average Change Percent | 0.15722318 |
| Fifty Two Week Change Percent | -59.95816 |
| Fifty Two Week High | 53.2 |
| Fifty Two Week High Change | -35.17 |
| Fifty Two Week High Change Percent | -0.6610902 |
| Fifty Two Week Low | 6.5 |
| Fifty Two Week Low Change | 11.530001 |
| Fifty Two Week Low Change Percent | 1.7738463 |
| Fifty Two Week Range | 6.5 - 53.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,612,535,400,000 |
| Float Shares | 34,495,813 |
| Forward Eps | -3.74217 |
| Forward P E | -4.8180604 |
| Free Cashflow | -188,829,120 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 76 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04271 |
| Held Percent Institutions | 0.69554 |
| Implied Shares Outstanding | 54,185,877 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-02-05 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,758,240,000 |
| Last Split Factor | 1:20 |
| Long Business Summary | Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. |
| Long Name | Vor Biopharma Inc. |
| Market | us_market |
| Market Cap | 976,971,392 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_572078292 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -883,080,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,037,117,685 |
| Number Of Analyst Opinions | 8 |
| Open | 18.88 |
| Operating Cashflow | -149,892,992 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 617 655 6580 |
| Previous Close | 19.14 |
| Price Eps Current Year | -2.6125817 |
| Price Hint | 2 |
| Price To Book | -6.494957 |
| Profit Margins | 0.0 |
| Quick Ratio | 30.573 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -1.11 |
| Regular Market Change Percent | -5.79937 |
| Regular Market Day High | 19.33 |
| Regular Market Day Low | 17.82 |
| Regular Market Day Range | 17.82 - 19.33 |
| Regular Market Open | 18.88 |
| Regular Market Previous Close | 19.14 |
| Regular Market Price | 18.03 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,107,749 |
| Return On Assets | -0.69759005 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 54,185,877 |
| Shares Percent Shares Out | 0.1429 |
| Shares Short | 7,743,558 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 4,818,351 |
| Short Name | Vor Biopharma Inc. |
| Short Percent Of Float | 0.1709 |
| Short Ratio | 5.41 |
| Source Interval | 15 |
| State | MA |
| Symbol | VOR |
| Target High Price | 50.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 37.875 |
| Target Median Price | 40.0 |
| Total Cash | 491,524,992 |
| Total Cash Per Share | 9.071 |
| Total Debt | 2,939,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -70.4 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 16.752775 |
| Two Hundred Day Average Change | 1.2772255 |
| Two Hundred Day Average Change Percent | 0.07623964 |
| Type Disp | Equity |
| Volume | 1,107,749 |
| Website | https://www.vorbio.com |
| Zip | 2,116 |